Cargando…
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNF...
Autores principales: | Dougados, Maxime, Wei, James Cheng-Chung, Landewé, Robert, Sieper, Joachim, Baraliakos, Xenofon, Van den Bosch, Filip, Maksymowych, Walter P, Ermann, Joerg, Walsh, Jessica A, Tomita, Tetsuya, Deodhar, Atul, van der Heijde, Désirée, Li, Xiaoqi, Zhao, Fangyi, Bertram, Clinton C, Gallo, Gaia, Carlier, Hilde, Gensler, Lianne S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025731/ https://www.ncbi.nlm.nih.gov/pubmed/31685553 http://dx.doi.org/10.1136/annrheumdis-2019-216118 |
Ejemplares similares
-
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
por: Landewé, Robert BM, et al.
Publicado: (2021) -
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022) -
Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022) -
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020) -
Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)